Showing results (1-10 of 380) with videos related to
Sort By:
Pageof 38
BMC Medicine|February 7, 2016
Advances in immunotherapy for melanomaJason M Redman, Geoffrey T Gibney, Michael B AtkinsJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2015
Swinging for the Fences: Long-Term Survival With Ipilimumab in Metastatic MelanomaGeoffrey T Gibney, Michael B AtkinsClinical Advances in Hematology & Oncology : H&O|September 10, 2015
Immunotherapy or molecularly targeted therapy: what is the best initial treatment for stage IV BRAF-mutant melanoma?Geoffrey T Gibney, Michael B AtkinsThe Lancet. Oncology|December 8, 2016
Predictive biomarkers for checkpoint inhibitor-based immunotherapyGeoffrey T Gibney, Louis M Weiner, Michael B AtkinsFrontiers in Oncology|January 31, 2022
Volume of Disease as a Predictor for Clinical Outcomes in Patients With Melanoma Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint TherapyAidan M Burke, Michael Carrasquilla, Walter C Jean, et al.Expert Opinion on Drug Metabolism & Toxicology|April 30, 2013
Clinical development of dabrafenib in BRAF mutant melanoma and other malignanciesGeoffrey T Gibney, Jonathan S ZagerThe Surgical Clinics of North America|September 24, 2014
Indications and options for systemic therapy in melanomaVernon K Sondak, Geoffrey T GibneyHematology/Oncology Clinics of North America|June 2, 2014
Surgical management of melanomaVernon K Sondak, Geoffrey T GibneyCancer Discovery|March 12, 2013
An unholy alliance: cooperation between BRAF and NF1 in melanoma development and BRAF inhibitor resistanceGeoffrey T Gibney, Keiran S M SmalleyCancer Journal (Sudbury, Mass.)|January 24, 2017
Targeted Therapies in Combination With Immune Therapies for the Treatment of Metastatic MelanomaShelly A Christiansen, Shaheer Khan, Geoffrey T GibneyPageof 38